Work

Neoadjuvant darovasertib in uveal melanoma patients undergoing primary local therapy (OptimUM-10): Phase 3 trial.

Year: 2026

Type: article

Study design: Study Protocol

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.tps9608

Authors: J. William Harbour, David Alan Reichstein, Martina Angi, Mandeep S. Sagoo, Roderick O'day, Marcus O. Butler, Heather May Shaw, Meredith McKean, Lotte S. Fog, Samuel T. Chao, John N. Waldron, Mwe Mwe Chao, Long Kwei, Jasgit C. Sachdev, Darrin M. Beaupre, Carol L. Shields

Institutions: The University of Texas Southwestern Medical Center, Tennessee Retina, Moorfields Eye Hospital, University College London, The Royal Victorian Eye & Ear Hospital, Princess Margaret Cancer Centre, University College Hospital, Sarah Cannon, Cleveland Clinic, University of Toronto, Ideaya Biosciences (United States), Wills Eye Hospital

Language: English

Topic: Ocular Oncology and Treatments

Subfield: Ophthalmology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162695392

FWCI: 7.414

Cites:

Cited by: 1

Related to: